KPV: What the Research Shows on the Anti-Inflammatory Tripeptide

The published research on KPV shows anti-inflammatory effects in cell culture and in mouse models, most prominently mouse models of colitis, and it has not been tested in a human trial. KPV is the three-amino-acid sequence lysine-proline-valine from the end of alpha-melanocyte-stimulating hormone, and when the FDA reviewed it in 2026 the agency reported finding no clinical studies or human exposure data for it by any route.

That leaves a small, coherent preclinical literature and an empty clinical one. The sections below take the studies in turn.

What it is

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide hormone best known for its role in skin pigmentation and inflammation. KPV corresponds to its last three residues, positions 11 to 13, which is why it is sometimes written alpha-MSH(11-13). The FDA notes that alpha-MSH acts through melanocortin receptors, with its anti-inflammatory effects attributed mainly to the MC3, MC4 and MC5 subtypes.

The interesting finding about KPV is that it does not appear to work the same way as its parent.

Mechanism: probably not the melanocortin receptors

Getting, Schiöth and Perretti (Journal of Pharmacology and Experimental Therapeutics, 2003) studied KPV in a mouse model of crystal-induced peritonitis. KPV reduced the accumulation of white blood cells in the abdominal cavity, and that effect was not blocked by a drug that blocks the MC3 and MC4 receptors. It also persisted in mice with a nonfunctional MC1 receptor. In cultured macrophages, KPV did not raise cyclic AMP, the signal melanocortin receptors normally produce. The authors concluded that KPV is unlikely to act through melanocortin receptors and more likely acts by inhibiting the effects of interleukin-1 beta, an inflammatory signaling protein.

The FDA's briefing document summarizes earlier in vitro work pointing the same way: KPV did not displace alpha-MSH from its binding sites in rat brain tissue, mouse melanoma cells or mouse macrophages.

Colitis models: the core of the literature

Dalmasso and colleagues (Gastroenterology, 2008), at Emory University, proposed how KPV gets into cells. PepT1 is a transporter for small peptides, normally found in the small intestine and induced in the colon during inflammatory bowel disease. In human intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and a human T-cell line (Jurkat), KPV at nanomolar concentrations inhibited NF-kappaB and MAP kinase inflammatory signaling and reduced inflammatory cytokine release, and the uptake experiments indicated it entered through PepT1. In two chemically induced mouse colitis models, DSS and TNBS, KPV given in drinking water reduced the incidence of colitis and lowered inflammatory cytokine expression.

Kannengiesser and colleagues (Inflammatory Bowel Diseases, 2008), at the University of Münster, tested KPV in two other mouse models: DSS colitis and T-cell transfer colitis. In both, KPV-treated mice recovered weight faster and showed less inflammation in colon tissue. In mice with a nonfunctional MC1 receptor given DSS, the authors reported that every KPV-treated animal survived the colitis. They concluded the effect was at least partly independent of MC1 receptor signaling.

Xiao and colleagues (Molecular Therapy, 2017), with Didier Merlin, senior author of the 2008 Emory study, among the authors, packaged KPV in hyaluronic acid-coated nanoparticles targeted to colon cells and macrophages and reported reduced mucosal damage and lower TNF-alpha in a mouse ulcerative colitis model, with the targeted version outperforming untargeted particles.

These are consistent findings across independent groups, which counts for something. They are also all rodent and cell models, with inflammation induced by chemicals or by transferring immune cells, which are useful laboratory tools and imperfect stand-ins for human disease.

Skin and wounds

The FDA's review lists rodent wound-healing studies of KPV and notes that researchers in the field have called for investigational clinical studies of it for skin wounds and ulcers. It also cites Pawar and colleagues (Journal of Pharmaceutical Sciences, 2017), who found in human cadaver skin that KPV does not permeate well through intact skin unless the barrier is disrupted, for example by microneedle abrasion or iontophoresis. That is a laboratory permeation result, not a clinical one.

What is missing

We found no published human trial of KPV for any condition. The FDA's briefing document for the July 2026 advisory meeting goes further: the nomination did not include, and FDA did not identify, any clinical studies or human exposure data for KPV via any route. The agency also reported that it did not identify pharmacokinetic, acute or repeated toxicity, genotoxicity, reproductive toxicity or carcinogenicity studies of KPV.

FDA staff described both KPV and KPV acetate as not well characterized, citing inconsistent naming, a lack of published quality-control data on impurities, aggregates and microbiological testing, and no certificate of analysis in the nomination package. Our explainer on HPLC purity and net peptide content covers why salt form and characterization matter when reading a certificate.

Regulatory status

KPV is not FDA-approved for any use. It was in Category 2 of the FDA's compounding policy, for substances that may present significant safety risks, and was removed in April 2026 after its nominator withdrew. At the July 23, 2026 meeting of the Pharmacy Compounding Advisory Committee, FDA staff proposed against adding KPV to the 503A bulks list, citing the absence of human data. The committee voted 8 to 6 with one abstention to recommend it. The recommendation is not binding and is not an approval, and we found no proposed rule as of this writing.

An interim access policy covering some peptides is now under White House review. Its list of covered substances has not been published.

For the rest of this group, see our review of the repair peptides and our comparison of BPC-157 and TB-500.

Frequently asked questions

What is KPV?

A tripeptide, lysine-proline-valine, matching the last three amino acids of alpha-melanocyte-stimulating hormone. It has been studied for anti-inflammatory activity in cells and mice.

Has KPV been tested in humans?

We found no published human trial. The FDA reported in 2026 that it identified no clinical studies or human exposure data for KPV by any route.

How is KPV thought to work?

Research suggests it does not act mainly through melanocortin receptors, unlike its parent hormone. Cell studies report reduced NF-kappaB inflammatory signaling, and a 2008 study proposed that KPV enters intestinal and immune cells through the PepT1 peptide transporter.

Is KPV FDA-approved?

No. An FDA advisory committee recommended it for the compounding bulks list in July 2026, against the recommendation of FDA staff, and that vote is not an approval.

Sources:

No compound discussed in this review is FDA-approved. Nothing above is dosing guidance or a treatment claim. Research use only.

For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication